GLP-1 Longitudinal Outcomes & Biomarkers Cohort

Whether the endpoint is tumor response, amyloid reduction, cardiometabolic outcome, or biomarker progression

— biopharma depends on the image. Yet every major real-world data platform is built from EHR, claims, or genomics outward. Imaging is secondary, ingested, or absent entirely.

Segmed is the only RWD platform built from imaging outward, with clinical context layered in at scale. The pre-built research cohorts below bring together imaging, treatment history, outcomes, and biomarkers in the specific therapeutic areas where the need is most acute.